Nethalide, a beta adrenergic blocking agent

Schröder, G.; Werkö, Lars

doi:10.1002/cpt196452159

Cited by 53 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional studies are indicated in order to understand the complex interaction of the drugs presently classified as f3-adrenergic blockers with the various structures which regulate hemodynamic functions. The antihypertensive effects of f3-blockers were first reported by PRICHARD [178], and by SCHR(lDER and WERKl) [179]. These findings could not have been anticipated either on the basis of knowledge about the functioning of the sympathetic nervous system or of the pathophysiology of hypertension.…”

Section: '-C'hconh~ochbhch2nhch(ch'12mentioning

confidence: 89%

Antihypertensive Agents

Wilhelm¹,

deStevens²

1976

Progress in Drug Research/Fortschritte Der Arzneimittelforschung/Progrés Des Recherches Pharmaceutiques

View full text Add to dashboard Cite

Section: '-C'hconh~ochbhch2nhch(ch'12mentioning

confidence: 89%

Antihypertensive Agents

Wilhelm¹,

deStevens²

1976

Progress in Drug Research/Fortschritte Der Arzneimittelforschung/Progrés Des Recherches Pharmaceutiques

View full text Add to dashboard Cite

“…Since sympathectomy has a favourable effect on patients suffering from angina pectoris, adrenergic beta-receptor blocking agents should have a similar effect. Schroder and Werko (14) have demonstrated that the energy requirement of the heart after pronetholol (Aderlin) administration is less, both for normal test subjects and for hypertensive patients. I t has been shown using both pronetholol (2, 3, 10, 8) and propranolol (10,17) that these substances diminish anginal distress and even inhibit the S-T depression of the working ECG.…”

Section: Discussionmentioning

confidence: 99%

Orthostatic ECG Changes and the Adrenergic Beta‐receptor Blocking Agent, Propranolol (Inderal)

Nordenfelt

1965

Journal of Internal Medicine

View full text Add to dashboard Cite

“…The first reports concerning the hypoten sive effect of beta-blockers were published in 1964 [7,8], Several factors have been sug gested to explain the hypotensive effect of these agents -an effect on the central nervous system, an adrenergic neuron-blocking effect, an effect secondary to reduced cardiac out put, and a mechanism consequent to reset ting the baroreceptors. The hypotensive ef fect of beta-blockers appears gradually and may take several weeks to reach its maxi mum [9], The beta-blockers in clinical use adrenergic receptors, but they differ in a vari ety of associated properties, such as the pres ence or absence of cardioselectivity, mem brane-stabilizing activity and ISA.…”

Section: Discussionmentioning

confidence: 99%

Effects of Oxprenolol versus Propranolol on Myocardial Performance and Myocardial O<sub>2</sub> Consumption in Hypertensive Patients

Schlesinger¹,

Ravid²,

Meshulam³

1983

Cardiology

View full text Add to dashboard Cite

The purpose of the study was to compare the effects of oxprenolol, a beta-adrenergic blocking agent with intrinsic sympathomimetic activity, to propranolol, a beta-blocker without intrinsic sympathomimetic activity, on myocardial performance and myocardial O₂ consumption (MVO₂). Myocardial performance was reflected by the systolic time intervals (STI) and MVO₂ by the triple product of heart rate × left ventricular ejection time × systolic blood pressure (HR × LVET × SBP). The trial, a double-blind cross-over study, included 32 hypertensive patients, 17 males and 15 females, with a mean age of 50.9 years. The patients were divided into two groups: group A – 16 patients who were treated with effective antihypertensive doses of oxprenolol and diuretics (Esidrex K) for the first 8 weeks (period I) and with similar doses of propranolol and diuretics for the following 8 weeks (period II); Group B – the same number of patients who received the same drugs in the reverse order. All patients were examined during both periods at 2- and 3-week intervals, blood pressure and heart rate were recorded, and patients were provided with the appropriate study medication. At the end of periods I and II, myocardial function was assessed on the basis of STI, and MVO₂ was evaluated on the basis of the triple product of HR × LVET × SBP. Four measurements of STI and MVO₂ were carried out for each patient at the end of periods I and II: prior to intake of medication and 1½, 3 and 4½ h after intake of medication. The results of the study indicated in all four measurements a tendency for lower myocardial performance in both groups following propranolol treatment as compared to oxprenolol. This tendency was more marked on the third and fourth measurements, during which higher blood levels are expected, and was statistically significant on measurement IV (p < 0.001, t = 3.5 for the ratios PEP/LVET). A slight tendency for lower values of MVO₂ following the treatment with propranolol as compared to oxprenolol was obtained (measurement I: t = 2.04, p < 0.05; measurement IV: t = 1.56, p < 0.05). It can be concluded that treating hypertensive patients with propranolol is accompanied by a somewhat lower myocardial function and a tendency for lower MVO₂ as compared to treatment with oxprenolol. Treatment with oxprenolol seems, therefore, to be superior to propranolol in patients with impaired myocardial function.

show abstract

Nethalide, a beta adrenergic blocking agent

Cited by 53 publications

References 4 publications

Antihypertensive Agents

Antihypertensive Agents

Orthostatic ECG Changes and the Adrenergic Beta‐receptor Blocking Agent, Propranolol (Inderal)

Effects of Oxprenolol versus Propranolol on Myocardial Performance and Myocardial O<sub>2</sub> Consumption in Hypertensive Patients

Contact Info

Product

Resources

About